 The primary objective of this study is to determine the overall response rate to erlotinib in patients with polycythemia vera PV. Response rate will be assessed by improvement in the complete blood count, ultrasound of the spleen, and JAK2 molecular status. It is purposed in this study to explore a possible molecular targeting of the driving mechanism of PV. 